Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells.

Novel GPR35 agonist

Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B)

Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor

Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel

Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model

Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo

Novel selective opioid receptor antagonist at all three receptor types

Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription

Novel long-acting β 2 -adrenoceptor agonist

Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway

Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models

Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1)

Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity

Novel antimalarial agent

Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease.

Novel monocyte/macrophage targeted histone deacetylase inhibitor

CCR2b receptor antagonist

Natural antibacterial agent, being active against gram-positive bacteria.

Potent and selective M1 antimuscarinic

Mucolitic agent, inhibiting activation of nuclear factor kappa-κB (NF-κB) by blocking phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)/IκB kinase (IKK) activities, showing the anti-inflammatory properties on inflammation-associated skin diseases

Photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck, also showing activity agaimst COVID-19 Mpro